Zymeworks Inc. Receives FDA Clearance for Investigational New Drug Application for ZW251, Targeting Hepatocellular Carcinoma
Zymeworks Inc., a clinical-stage biotechnology company, has announced the U.S. Food and Drug Administration (FDA) clearance of their investigational new drug $(IND.AU)$ application for ZW251. This novel glypican 3-targeted antibody-drug conjugate $(ADC)$ is designed to treat hepatocellular carcinoma $(HCC)$, the most common form of primary liver cancer. The IND clearance allows Zymeworks to initiate a Phase 1 clinical trial for ZW251, expected to begin in 2025. This marks the second ADC from Zymeworks' pipeline, utilizing their proprietary topoisomerase 1 inhibitor payload. Preclinical studies have shown ZW251 to have strong anti-tumor activity and a favorable tolerability profile, offering potential improvements over current HCC treatments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9501215-en) on July 28, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。